<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162837</url>
  </required_header>
  <id_info>
    <org_study_id>OAT-0110</org_study_id>
    <nct_id>NCT01162837</nct_id>
  </id_info>
  <brief_title>Safety &amp; Effectiveness of the BEAM Device in Mild-to-moderate Acne</brief_title>
  <official_title>An Evaluation of the Safety and Effectiveness of the BEAM Device in the Treatment of Mild-to-moderate Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Aesthetic Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Aesthetic Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if the use of the BEAM device reduces the signs and symptoms of
      mild-to-moderate acne.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in inflammatory lesion count</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction in the number of inflammatory acne lesions on one side of the face after 8 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Acne Severity Score</measure>
    <time_frame>8-weeks</time_frame>
    <description>Reduction in the Global Acne Severity Score at 8-weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects are enrolled in this arm and will use the BEAM device on one side of the face and the other side of the face will be the control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BEAM device</intervention_name>
    <description>A red/blue LED device for the treatment of acne</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 15 years or older of either gender and of any racial/ethnic group.

          2. At least 8 acne inflammatory lesions (see section 9) in the treatment and control
             areas.

          3. Presence of clinically-evident facial acne of mild-to-moderate severity (score 2-4 on
             the Global Acne Severity Scale, see below)

          4. Subjects must be in generally good health.

          5. Subjects must be able and willing to comply with the requirements of the protocol.

        Exclusion Criteria:

          1. Oral retinoid use within six months of entry into the study.

          2. Systemic acne therapies (oral antibiotics) within 2 weeks of entry into the study.

          3. Topical acne therapies (retinoids, antibiotics) within 1 week of entry into the study.

          4. Microdermabrasion or superficial chemical peels at the site to be treated within 2
             months of entry into the study.

          5. Subjects with a history of dermabrasion or laser resurfacing at the site to be
             treated.

          6. Use of topical lipid absorbing substances (Clinac AC) within 1 week of entry into the
             study.

          7. Non-compliant subjects.

          8. Subjects with a significant medical history or concurrent illness/condition which the
             investigator(s) feel is not safe for study participation.

          9. Subjects using alcohol-based topical solutions or &quot;exfoliating&quot; agents within 1 week
             of entry into the study.

         10. Subjects with a history of very frequent herpes simplex infections of the face or with
             clinical evidence of active herpes simplex infections.

         11. Pregnant or nursing females.

         12. Subjects with known photosensitivity disorders felt by the investigators to preclude
             safe inclusion in the study.

         13. Subjects who have a history of significant post-inflammatory hyperpigmentation at the
             sites of acne lesions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Ehst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baumann Cosmetic &amp; Research Institute</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology &amp; Research Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

